Fig. 5.

Detection of long-term synergism in vitro and in vivo. a Analysis of cell proliferation using a SRB assay 7 days after treatment with Palbociclib (1000 nM) or in combination with Axitinib (1000 nM), Erdafitinib (5000 nM), NVP-BEZ235 (200 nM) and CI1040 (1000 nM) (*, P < 0.05; one-way ANOVA with Dunnett’s multiple comparisons test, combination therapies compared to respective monotherapies and non-treated control, data represent the mean ± SD of 3 replicates). b RT112-Luc xenografts were treated as described and size was measured by quantification of the luminescence signal, representing the number of viable cells (*, P < 0.05; one-way ANOVA with Dunnett’s multiple comparisons test, combination therapies compared to respective monotherapies and non-treated control)